-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Mineralys Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2022 to 2024.
- Mineralys Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$51.8M, a 86.8% decline year-over-year.
- Mineralys Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$192M, a 127% decline year-over-year.
- Mineralys Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$192M, a 127% decline from 2023.
- Mineralys Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$84.7M, a 169% decline from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)